946: Myocardial Injury Among Hospitalised Patients With COVID-19 Associated With Higher Risk of Death

DG News Myocardial injury is prevalent among patients hospitalised with coronavirus disease 2019 (COVID-19) and is associated with higher risk of mortality, according to a study published in the Journal of the American College of Cardiology.

Anu Lala, MD, Icahn School of Medicine at Mount Sinai, New York, New York: “We found that 36% of patients who were hospitalised with COVID-19 had elevated troponin levels and were at higher risk of death. These findings, which are consistent with reports from China and Europe, are important for clinicians. If COVID-19-positive patients arrive in the emergency room and their initial test results show troponin levels are elevated, doctors may be able to better triage these patients and watch over them more closely, but this remains a testable hypothesis.”

Researchers analysed electronic health records of nearly 3,000 adult patients with confirmed positive COVID-19 admitted to 5 New York City hospitals within the Mount Sinai Health System between February 27, 2020, and April 12, 2020. The median age for patients analysed was 66 years and about 60% were male. One-quarter of all patients self-identified as African American and 27% self-identified as Latino. Roughly 25% of the patients had a history of heart disease and 25% had cardiovascular disease risk factors.

All patients had a blood test for troponin levels within 24 hours of admission, of which 64% had normal levels (0.00-0.03 ng/mL), 17% had mild elevation (>0.03-0.09 ng/mL), and 19% had higher elevation (>0.09 ng/mL). Higher troponin levels were more prevalent in patients who were aged older than 70 years old and had previously known conditions including diabetes, hypertension, atrial fibrillation, coronary artery disease, and heart failure.

Patients with milder forms of myocardial injury were associated with lower likelihood of hospital discharge and a 75% higher risk of death compared with patients with normal levels.

Patients with higher troponin concentrations were associated with a 3 times higher risk of death compared with those with normal levels. When adjusting for relevant factors such as heart disease, diabetes, and hypertension, troponin was independently associated with risk of death. More specifically, heart injury seems to be a more important indicator in predicting risk of death than a history of heart disease.

Reference: https://www.sciencedirect.com/science/article/abs/pii/S0735109720355522

Thursday, January 17, 2019

Do not ignore raised cardiac troponin even in patients without a specific diagnosis

Ignore elevated cardiac troponin in patients without a specific diagnosis at your own peril, cautions a new retrospective registry-based cohort study of more than 45,000 patients in the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry.

The study is published online Jan. 7, 2019 in the Journal of the American College of Cardiology.

Most patients included in the study had been hospitalized for chest pain with clinically suspected acute coronary syndrome (ACS). Fifteen percent of patients developed a major adverse event (MAE; mortality, ACS, heart failure, or stroke) during a median follow-up of 4.9 years. The risk for MAE was associated with higher cardiac troponin (cTn). The hazard ratio for highest assay-specific cTn tertile was 2.59.

Notably, in patients without cardiovascular comorbidities, renal dysfunction, left ventricular dysfunction, or significant coronary stenosis the hazard ratio was 3.57.

The study concluded that raised cardiac troponin is a predictor for an impending MAE even in patients with no evidence of coronary artery disease, heart failure, or kidney dysfunction and hence should not be ignored. It is not just enough to rule out an acute ischemic event.

These patients should be investigated carefully with modalities such as echocardiography and angiography. And, even if the tests do not conclusively establish coronary disease, they should still be closely monitored and be given cardioprotective medications such as statins, ACEIs.

The Fourth universal definition of myocardial infarction (2018) has for the first time differentiated myocardial injury from myocardial infarction (Eur Heart J. 2019;40:237-69). It also recognizes myocardial injury as an entity in itself even though it is essential for the diagnosis of acute myocardial infarction. It states: “The term myocardial injury should be used when there is evidence of elevated cardiac troponin values (cTn) with at least one value above the 99th percentile upper reference limit (URL). The myocardial injury is considered acute if there is a rise and/or fall of cTn values.”

“The term acute myocardial infarction should be used when there is acute myocardial injury with clinical evidence of acute myocardial ischaemia and with detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL and at least one of the following:

· Symptoms of myocardial ischaemia

· New ischaemic ECG changes

· Development of pathological Q waves

· Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology

· Identification of a coronary thrombus by angiography or autopsy (not for types 2 or 3 MIs)”

(Source: Medscape, JACC, European Heart Journal)

Dr KK Aggarwal

Padma Shri Awardee

President Elect Confederation of Medical Associations in Asia and Oceania (CMAAO)

Group Editor-in-Chief IJCP Publications

President Heart Care Foundation of India

Past National President IMA